The development of GluN1-P2, a therapeutic peptide that competitively inhibits this B2M-GluN1 interaction, has demonstrated significant improvements in synaptic plasticity and cognitive performance in both DS and aging mouse models [87]. This evidence concerns the gene B2M and Dravet syndrome.